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Genotypic  monitoring  of  drug-resistance  mutations  (DRMs)  in  HIV-1  infected  individuals  is strongly  rec-
ommended  to guide  selection  of  the initial  antiretroviral  therapy  (ART)  and changes  of drug  regimens.
Traditionally,  mutations  conferring  drug  resistance  are  detected  by  population  sequencing  of  the reverse
transcribed  viral  RNA  encoding  the  HIV-1  enzymes  target  by ART,  followed  by  manual  analysis  and  inter-
pretation  of Sanger  sequencing  traces.  This  process  is  labor  intensive,  relies  on  subjective  interpretation
from  the operator,  and  offers  limited  sensitivity  as  only  mutations  above  20%  frequency  can  be  reliably
detected.  Here  we present  MinVar,  a  pipeline  for the analysis  of  deep  sequencing  data,  which  allows
reliable  and automated  detection  of  DRMs  down  to  5%.  We  evaluated  MinVar  with  data  from  ampli-
con  sequencing  of  deﬁned  mixtures  of molecular  virus  clones  with  known  DRM  and  plasma  samples  ofioinformatics
rug resistance mutations
inority variants
viremic  HIV-1  infected  individuals  and  we compared  it to  VirVarSeq,  another  virus  variant  detection  tool
exclusively  working  on Illumina  deep  sequencing  data.  MinVar  was  designed  to  be  compatible  with  a
diverse  range  of  sequencing  platforms  and  allows  the  detection  of DRMs  and  insertions/deletions  from
deep  sequencing  data  without  the need  to perform  additional  bioinformatics  analysis,  a prerequisite  to  a
widespread  implementation  of  HIV-1  genotyping  using  deep  sequencing  in routine  diagnostic  settings.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Genotyping of the HIV-1 pol gene, which encodes the viral
nzymes targeted by current ART, has become a standard of care
nalysis conducted by clinical virology laboratories in many coun-
ries. The population of HIV-1 present in a patient’s blood is
equenced to discover mutations associated with drug resistance
hat would reduce efﬁcacy of speciﬁc antiretroviral drugs. The
redominant method used to detect drug resistance mutations
DRMs) is currently population sequencing based on the Sanger
echnology. Advancements in sequencing technologies made over
he last ten years have, however, opened new possibilities to
ncrease sensitivities and are considered to eventually replace cur-
ent methods. Detecting low frequency mutations with Sanger
equencing is challenging as it requires the interpretation of low
∗ Corresponding author.
E-mail address: zagordi.osvaldo@virology.uzh.ch (O. Zagordi).
1 M.H. and K.J.M. contributed equally to this work.
ttp://dx.doi.org/10.1016/j.jviromet.2016.11.008
166-0934/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
intensity peaks appearing in the electrophoretogram. Although
automated systems are available, this interpretation must often
be conducted manually, thus it is operator dependent and labor
intensive, offers poor sensitivity and limited reproducibility. A
20% frequency is commonly considered the lowest threshold at
which mutations can be detected, although even at this frequency
mutations are frequently missed (Schuurman et al., 2002). Mas-
sively parallel sequencing (MPS), also known as deep sequencing
or next-generation sequencing (NGS), has the potential to surpass
the limitations of population sequencing based on the Sanger tech-
nique (St John et al., 2016; Wang et al., 2007). The sheer volume of
bases that can be sequenced in a single run allow for an extremely
deep coverage of the region of interest. This coverage, if combined
with a careful correction of sequencing errors, could in principle
lower the limit of mutant detection to a single viral copy, and hence
should easily allow the detection of very low frequency mutations
and even the co-occurrence of different mutations on the same
viral strain (Beerenwinkel et al., 2012; Beerenwinkel and Zagordi,
2011). In practice, however, NGS analysis faces limitations in reach-
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ng this high sensitivity mainly because of the high error rate of the
RT-)PCR (Di Giallonardo et al., 2013; Welkers et al., 2014). Nev-
rtheless, deep sequencing of artiﬁcial mixtures of viral plasmids
sing Roche 454 pyrosequencing showed that variants at frequen-
ies below 1% can be detected (Zagordi et al., 2010). Similar results
ave been reported for the Illumina Miseq platform (Ode et al.,
015; B. Verbist et al., 2015). Yet, the use of these technologies in
iagnostic practice requires additional considerations. In such an
nvironment the application does not only have to guarantee sen-
itivity and speciﬁcity, but it must also offer consistent results. This
an be speciﬁcally challenging for HIV-1 with the inherently high
equence variability of subtypes. Likewise, the broad application of
GS-based diagnostics is only feasible if the system is easy to use
ithout necessitating bioinformatics expertise and requires short
omputing time.
Here we present a computational pipeline for HIV-1 genotyp-
ng, MinVar, that addresses these constraints and aims at replacing
he subjective interpretation of population Sanger sequencing
urrently required in routine HIV-1 genotyping. Our pipeline
ncompasses several state-of-the-art tools already available for the
nalysis of sequencing data and allows in an easy work ﬂow to go
rom the raw sequencing reads to a list of amino acid mutations
nnotated with their frequencies combined with information from
he Stanford HIV database (Rhee et al., 2003) to highlight those
onferring resistance to antiviral drugs (an example of its output
s reported in Table S1). We  carefully evaluated our procedure by
omparing it to VirVarSeq and analyzing deﬁned mixtures of HIV-1
irus stocks harboring distinct mutations. While the two  tools show
 good concordance for medium to high frequency variants, results
iverge to some extent for low frequency variants for which Min-
ar proved more conservative than VirVarSeq. This was achieved
y applying a higher frequency threshold to call a variant (1.5% vs.
.5%) which translates into achieving a better precision with only a
inor reduction in recall. Nevertheless, our results, obtained using
NA as starting material, recommend great caution in reporting
utations below 5%. However, the ability to report mutants down
o a 5% threshold combined with the ease of use and higher preci-
ion of MinVar opens the possibility for a wide spread use of deep
equencing technologies. Finally, while VirVarSeq was developed
s a tool for Illumina sequencing data only, we showed MinVar
ersatility by successfully using it on data from Roche 454 GS Junior.
. Methods
.1. Software
MinVar is an application written in Python that is invoked as
 single command without need to specify options or parameters.
he input is a set of overlapping reads (either from amplicons or
hotgun) covering the HIV-1 pol region, where proteins target of
nti-retroviral drugs are coded. The ﬁle must be in fastq format
standard output format for sequencing platforms).
The main output is a table with amino acid mutations with
espect to HIV-1 consensus B, annotated according to the class
f resistance deﬁned in the Stanford HIVdb. In order to run the
nnotation locally, MinVar includes consensus B sequence, its
ucleotide equivalent, and other data from HIVdb version 7.0 (see
ttps://hivdb.stanford.edu/page/release-notes/).
For samples with large read numbers, i.e. on Illumina Miseq runs,
inVar limited the size of the input and, consequently, the cover-
ge, by randomly drawing 200,000 high quality reads per sample
rom the input ﬁle. For the experiments shown here, this corre-
ponds to a coverage of the order of 104; sufﬁcient to detect low
requency mutations and have a fast execution time. In the version
sed here the frequency threshold on mutations is 1.5%.al Methods 240 (2017) 7–13
MinVar relies on other state-of-the-art bioinformatics algo-
rithms for different stages of its pipeline, such as bwa (Li, 2013)
for read alignment and GATK (DePristo et al., 2011) for base quality
recalibration. The variant calling workhorse is LoFreq2 (Wilm et al.,
2012), a fast and sensitive variant caller capable of calling both sin-
gle nucleotide variants and indels. MinVar is speciﬁcally designed
to coordinate the application of these tools to the problem of calling
drug resistance mutations in HIV-1 populations. Further informa-
tion on MinVar and a link to the source code are available on the
website http://git.io/minvar
To verify the performance of MinVar we compared it to Vir-
VarSeq (B.M. Verbist et al., 2015) as this is, to the best of our
knowledge, the only other variant caller for virus populations that
calls mutations at the codon level. VirVarSeq was run without
the mixture model step, by using a quality threshold of 30, and
only reporting variants above 0.5%. Modelling the mixture was
not possible because of several instances where VirVarSeq failed,
probably due to the fact that the distribution of quality scores
in Illumina Miseq data has some gaps (personal communication
by VirVarSeq author). In order to have a fair comparison, also
VirVarSeq was  run on 200,000 randomly selected reads. Variant
calling for Sanger sequencing runs was done by manually inspect-
ing the electrophoretograms and using extended nucleotide codes
for ambiguous bases.
2.1.1. Reproducibility
Scripts used for making tables and ﬁgures reported in this
paper are available at the url http://github.com/ozagordi/MinVar
ms  analysis Plots were created in R (R Foundation for Statistical
Computing, 2014) with package ggplot2 (Wickham, 2009), work-
ﬂows were written with Snakemake (Köster and Rahmann, 2012).
Sequencing reads are deposited in Zenodo repository (doi:10.5281/
zenodo.44921).
2.2. Virus mixtures
In order to create a test panel for our drug resistance pipeline,
virus stocks of ﬁve different HIV-1 subtype B clones that harbored
different mutations in pol were mixed at different ratios as shown
in Table S2. The molecular HIV-1 mutants used were INP0224,
INP0223, INP0157, JRCSF (GenBank: M38429) and YU2 (GenBank:
M93258). The INP mutants were chosen as each one contains sev-
eral major drug resistance mutations (Table S3).
The proportions were chosen as follows: In the ﬁrst one, called
“GEO” as in “geometric”, the frequency of an isolate is half of a sec-
ond one, ranging from 50% to 3% (see Table S2). In mix  20-20 all
ﬁve viruses have a frequency of 20%. Mixes 60-10, 80-5 and 90-2.5
are composed of HIV-1 JRCSF at 60%, 80% and 90%, respectively, and
of each of the other isolates at 10%, 5%, 2.5%, respectively. The suf-
ﬁxes 1E5 and 1E4 indicate the respective viral titer (copies/mL). Mix
number (9–13 and 17–21) follows the denomination used in the
deposited dataset (doi:10.5281/zenodo.44921). Additionally, two
samples consist of JRCSF clonal viral stock at two different titers
(104 and 106 copies/mL). More details can be found in supplemental
methods.
2.3. Patients
Two sets of patient-derived samples were selected from clini-
cal specimens sent to our institute for routine HIV-1 drug resistance
testing, previously analyzed by routine Sanger population sequenc-
ing, and analysed with different methods for this study.A ﬁrst set of 10 patients’ samples, with HIV-1 subtype B infection
that covered a large range of virus titers (HIV-1 RNA between 450
and 900,000 copies/mL, see Table S4) was sequenced both on the
Illumina Miseq and Roche/454 GS Junior platform. A second set of
rologic
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4 patients of diverse subtypes and circulating recombinant forms
12 HIV-1 subtype B, 3 subtype A1, 3 subtype C, 3 CRF01 AE and 3
RF02 AG) was sequenced on the Miseq platform only (HIV-1 RNA
etween 300 and 220,000 copies/mL, see Table S4).
.4. Sequencing
Virus mixture or patient plasma were extracted and a 1st round
CR amplicon, which was later used in all sequencing methods,
as generated using the PrimeScript One Step RT-PCR Kit (Takara,
usatsu, Japan, amplicon length 3.5 kb, 20 cycles).
For Sanger population sequencing, a fragment covering pro-
ease and reverse transcriptase was ampliﬁed (1.7 kb, 40 cycles).
equencing was done with the BigDye Terminator v3.1 cycle
equencing kit (LifeTechnologies, Switzerland) and a 3130xl
enetic analyzer (Applied Biosystems, Switzerland). The elec-
rophoretograms of the sequences were assembled and manually
dited with the proofreader tool from IDNS (Integrated Database
etwork System) by SmartGene (Lausanne, Switzerland).
For 454 pyrosequencing, seven overlapping amplicons were
enerated with the goal to cover most of the protease and
everse transcriptase by at least two amplicons (median amplicon
ength 530 bp, 35 cycles). Pooled and puriﬁed PCR products were
equenced with the GS Junior Titanium emPCR technology on a
oche 454 GS Junior for 200 cycles.
For Illumina sequencing, a fragment was ampliﬁed that cov-
rs protease, reverse transcriptase and integrase (3.2 kb, 40 cycles).
exteraXT libraries of this amplicon were sequenced on a Illumina
iSeq for 1 × 250 cycles.
More details can be found in supplemental methods.
. Results
.1. Validation of MinVar using deﬁned molecular virus stock
ixtures
In order to test the performance of our pipeline in detect-
ng minority variants, we sequenced different mixtures of clonal
irus stocks with drug resistance mutations with the Illumina
iseq sequencing system. We  found a good agreement between
he expected frequencies and those estimated by MinVar. Scatter-
lots in Fig. 1 show the expected and observed frequencies of all
utations for the two test samples where each virus was  present
t approximately 20% (20-20 1E5 and 20-20 1E4). False positives
ppear as dots on the line x = 0, while false negatives as dots on the
ine y = 0. Of note, while no false positive above 10% was detected
t the lower viral load input sample, none above 5% was  detected
n the sample with the higher viral load. We  saw a similar pattern
or the remaining test mixtures analyzed (Figs. S1–S5).
Interestingly, frequencies of observed mutations showed a
arked spread around their expected value (Fig. 1 and Figs. S1–S5).
ndersampling of some virus stocks might explain this pattern,
o we analyzed frequencies of mutations grouped by clones. From
he same mixtures analyzed in Fig. 1, the subset of mutations that
re found on a single clone were extracted and their frequencies
eported in boxplots in Fig. 2. As an effect of undersampling alone
hese mutations should have a frequency different from 20%, but
qual for those coming from the same clone. However, we observed
 more complex pattern, and two remarkable features appear: i) a
trong deviation from the expected frequencies of 20%, which is
ore pronounced for the mixes of lower viral loads; ii) frequen-ies of mutations found on the same stock still show a substantial
eviation from one another (10% and more). The deviation between
iruses (i) supports the undersampling hypothesis, while the vari-
tion within viruses (ii) can be explained by a bias in the Nexteraal Methods 240 (2017) 7–13 9
XT preparation and not by a bias in PCR. Since one only amplicon
is ampliﬁed in the Illumina workﬂow, any PCR ampliﬁcation bias
would affect every mutation found on a given virus in the same
way.
We  next sought to evaluate the overall performance in detect-
ing mutations as a function of their expected frequency across
algorithms. Illumina Miseq data were analysed with both MinVar
and VirVarSeq. Precision and recall were computed for mix 20-
20, 60-10, 80-5 and 90-2.5 only for mutations expected to be at
the lowest frequency in the given mix. Thus, for these mixes, we
only considered mutations expected to be at 20%, 10%, 5% and 2.5%,
respectively. Precision and recall for these virus mixtures, on differ-
ent platforms and tools, are reported in Fig. 3a and b, respectively.
Precision, also known as positive predictive value, is the fraction of
mutations that are true out of all mutations detected. Recall, also
known as sensitivity, is the fraction of mutations detected out of all
mutations that are present. A summary measure of precision and
recall, the F1 score (deﬁned as their harmonic mean) is reported in
the supplement (Fig. S11). Mutations are reliably detected for 20%,
10% and 5%, while there is a marked reduction at 2.5% for all com-
binations of technology/analysis pipeline used. Sanger sequencing
suffers a bad performance already at 10%. VirVarSeq has been
shown to reliably call variants down to 0.5% frequency in the orig-
inal publication, where it was tested on mixtures of plasmids. We
chose for MinVar a higher threshold (1.5%) because our starting
material is RNA. With this choice MinVar achieves markedly higher
precision by losing only slightly in recall with respect to VirVarSeq.
In order to have another estimate of the error introduced by
the laboratory workﬂow, clonal JRCSF virus was  prepared at viral
titers of 104 and 106 copies/mL, i.e. also at a titer higher than the
mixes. These samples were sequenced on both Roche 454 and Illu-
mina Miseq and the data were analysed with MinVar. A total of
27 unexpected mutations were observed, 21 of these mutations
(78%) are found at a frequency up to 5%, very few even higher. More
mutations were found on 454 and at the lower titer, conﬁrming the
observations made on the mixes (Fig. S13).
Finally, we tested the robustness of our analysis to random
resampling of sequencing reads. Fastq ﬁles for mixes 80-5 1E4 and
80-4 1E5 were resampled three times, each time choosing 200,000
reads randomly. Mutations above 5% overlap entirely. Resampled
datasets of mix  80-5 1E5 disagree on a single mutation at around 2%
that is not present on any of the original viruses (data not shown).
3.1.1. MinVar on 454 pyrosequencing data
To demonstrate that MinVar is not restricted to a single sequenc-
ing platforms we applied it to sequencing data generated with
the Roche 454 GS Junior system and converted from sff to fastq
with SeqIO.convert from Biopython. Scatterplots in Figs. S6–S10
show the expected and observed frequencies for all viral mixes.
As for Illumina Miseq data, false positives and false negatives are
observed at low frequencies only, although they tend to be higher
than in the mixes sequenced on Illumina Miseq. Also on GS Junior
there is a marked spread of the frequencies around the expected
value. By analyzing the frequencies of mutations found on individ-
ual clones (Fig. S12) we  observe deviations similar to those found
for Miseq (Fig. 2). Since Nextera XT is not part of the GS Junior
workﬂow, the variation within viruses can be here attributed to the
presence of an ampliﬁcation bias for the (seven) different ampli-
cons.
3.1.2. Calling insertion/deletions
The presence of indels typically requires extra care in callingmutations, so the ability of each system to detect deletions was
speciﬁcally assessed. One virus, namely INP0157, has a deletion
within the RT gene at position 67. Table 1 reports the frequency
of INP0157 in different virus mixtures, and thus the frequency
10 M. Huber et al. / Journal of Virological Methods 240 (2017) 7–13
Fig. 1. Scatter plot showing expected and observed frequency for mutations found in mixtures 20-20 1E4 (left) and 20-20 1E5 (right). In these mixtures all viruses are
expected to be present at 20% frequency, hence mutations are expected at 20%, 40% and 60%, depending on whether one, two or three viruses harbor them (no mutation is
present on four or ﬁve viruses). Mixtures were prepared at viral titers of 104 (left) and 105 (right) copies/mL, sequenced on Illumina Miseq and analyzed with MinVar. Each
symbol  is a mutant amino acid with respect to consensus B, circles and triangles indicate mutations found on protease and on RT, respectively. A horizontal jitter has been
added  to avoid cluttering of too many points.
Fig. 2. Boxplots showing the frequency of mutations that are unique to each virus. Distributions of mutations expected at 20% in Fig. 1 are reported here separately for each
v ias, w
r
a
r
T
a
t
o
1irus.  Deviation from the expected 20% frequency can be explained by sampling b
egions of the amplicon.
t which we expect to detect this deletion, and the frequency
eported by MinVar for both Illumina Miseq and 454 GS Junior data.
he detection of indels by VirVarSeq requires a separate analysis
nd is not included in the standard pipeline. As reported in Sec-
ion 3.1, considerable deviation from the expected frequencies is
bserved. Both technologies detect the deletion reliably down to
0% at both viral loads. On Illumina MiSeq, the lowest expectedhile deviation within viruses by the effect of Nextera XT protocol on the different
frequency detected is 5% (measured 5.5%; excluding the outlier of
8.8% measured when expected at 2.5%). Although 454 pyrosequenc-
ing is more prone to indel errors, the better result here seems to
come from 454 GS Junior that detects this deletion down to 3.2% at
the higher viral load. However, this platform has an overall lower
performance than Illumina Miseq.
M. Huber et al. / Journal of Virological Methods 240 (2017) 7–13 11
Fig. 3. Precision (a) and recall (b) for all virus mixtures, sequencing platforms and analysis
virus  and at the lowest frequency in each mix, i.e. at 20%, 10%, 5% and 2.5%. On the left co
on  the right one at 105 copies/mL.
Table 1
Detection of deletion of amino acid D67 on RT with MinVar pipeline (n.d.: not
detected).
mix  Mix  name Miseq 454 expected Virus titer
9 GEO 1E5 n.d. 4.2 3.2 100,000
10  20-20 1E5 20.3 16.3 20 100,000
11  60-10 1E5 13.9 6.8 10 100,000
12  80-5 1E5 5.5 n.d. 5 100,000
13  90-2.5 1E5 8.8 8.4 2.5 100,000
17  GEO 1E4 n.d. n.d. 3.2 10,000
18  20-20 1E4 10.7 16.5 20 10,000
19  60-10 1E4 5.7 15.1 10 10,000
3
p
p
t
s
M20  80-5 1E4 n.d. 3.4 5 10,000
21  90-2.5 1E4 n.d. n.d. 2.5 10,000
.2. Application to clinical samples
To test our pipeline on patient samples, HIV-1 extracted from
lasma of 34 HIV-1 infected patients was sequenced on the Miseq
latform and also analyzed according to the routine clinical pro-
ocol based on Sanger. Patients were infected with diverse HIV
ubtypes (see Section 2.3 in Methods and Table S4) showing that
inVar is applicable over different subtypes. Results for patient 2 tools. The analysis is limited to those mutations that are expected to be on a single
lumn of each subﬁgure virus mixtures at viral titers of 104 copies/mL are reported,
(viral load 2800 copies/mL) are presented in Table 2. Miseq data
were analyzed with MinVar, and percent frequencies obtained are
listed in the table next to each detected mutation. There is a good
general agreement between Illumina Miseq and Sanger aside from
the ability of Miseq to detect many mutations at a frequency lower
than 20%. Position 123 on RT is peculiar as here another advan-
tage of deep sequencing appears: Four possible amino acids are
reported by Sanger because of two  ambiguous base calls on the ﬁrst
and third position of the codon ([A/G]A[A/C] or RAM using code for
ambiguous bases). As the exact co-occurrence of these bases on
the same virus cannot be determined with Sanger all four amino
acids are considered (AAA → K, AAC → N, GAA → E, GAC → D). Con-
versely, deep sequencing easily discerns which combinations are
found on the same read. Miseq data indicate a 100% mutation to E.
Results for the other patients are presented in the supplements as
a single csv ﬁle.
3.2.1. Roche 454 GS Junior on ten patients’ data
HIV-1 from plasma of patients 1–10, all infected with subtype B,
was also sequenced on Roche 454 GS Junior. Many low frequency
mutations not reported with Miseq are called in GS Junior data
(Table 1 and Supplementary data). In view of the results obtained
12 M. Huber et al. / Journal of Virologic
Table 2
Comparison of Miseq, 454 (both analyzed with MinVar) and Sanger sequencing for
patient 2. The number next to each amino acid letter is the percent frequency at
which it is detected. Position 123 on RT is characterized by two  variant nucleotides
on the same codon. Since Sanger Sequencing cannot phase these two mutations, all
four possibilities are reported.
gene pos wt  MinVar 454 Sanger MinVar Miseq
protease 6 W * 04
protease 16 G W 05
protease 18 Q R 03
protease 22 A D 04
protease 64 I V 05
protease 69 H Y 13
protease 93 I F 04
protease 96 T S 11
RT 31 I T 07
RT 35 V T 84 T T 99
RT 49 K R 92 R R 100
RT 50 I V 08
RT 53 E D 86 D D 100
RT 60 V I 92 I I 100
RT 67 D H 08
RT  77 F L 11
RT 83 R K 08
RT  102 K R 10
RT 123 D E 88 K-N-E-D E 100
RT 159 I V 05
RT 161 Q L 04
RT 162 S D 91 D D 94
RT 166 K R 100 R R 100
RT 173 K E 91 E E 100
RT 176 P S 83-Q 05 S S 100
RT 184 M V 94 V V 100
RT 200 T A 57 A A 100
RT 214 F V 04
RT 221 H I 05-Q 03
RT  222 Q K 14
RT  224 E Q 04
RT  272 A P 84-T 05 P P 100
RT 277 K R 97 R R 100
RT 293 I T 03
RT 297 E A 97 A A 100
RT 308 E Q 06
o
n
a
4
w
t
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e
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tRT  322 S L 06
RT 327 A E 05
n the controlled virus mixtures, we are conﬁdent that these calls
eed to be treated with caution and should be mostly considered
s false positives.
. Discussion
Here, we report on the development and evaluation of a soft-
are, MinVar, to detect HIV-1 drug resistance mutations, with
he aim to advance current methodologies used for routine test-
ng in clinical virology laboratories. We  compared MinVar to an
xisting analysis tool, VirVarSeq, speciﬁcally developed for Illumina
ata and evaluated the performance of MinVar using both Sanger
equencing and two different deep sequencing platforms.
The sample test panel chosen for this comparison was a set of
ve deﬁned virus stocks carrying a range of pol mutations that were
ixed at various proportions and viral load levels. Deep sequencing
latforms applied to the detection of viral diversity and the related
oftware tools are often evaluated by mixing known DNA plasmids
Thys et al., 2015; B. Verbist et al., 2015; B.M. Verbist et al., 2015;
agordi et al., 2010). Sometimes only two strains are used, differ-
ng by only a few nucleotides (Thys et al., 2015; B. Verbist et al.,
015; B.M. Verbist et al., 2015). Here, by using viral RNA as start-
ng material and different viral load input as is the case in clinical
amples where plasma virus is assessed, our control set is relevant
ecause it captures in a more realistic way possible error sources
hat can impact on the readout. As we highlight in our analysis,al Methods 240 (2017) 7–13
although deep sequencing is in principle able to detect mutations
at frequencies around 1% and lower, considering the error rates of
the RT-PCR, 5% should be considered as conservative but reliable
threshold for the detection of drug resistance mutations in clini-
cal practice. We base this estimation on the variant frequencies in
unmixed samples and the drop in precision/recall below 5%. Even
with a 5% threshold, deep sequencing is considerably more sen-
sitive than the currently applied methods in routine diagnostics
laboratories. Although lower frequency drug resistance mutations
are certainly present, their clinical relevance is currently not known
and they are therefore not considered for guiding treatment adap-
tations by major algorithms (Li and Kuritzkes, 2013). We compared
MinVar to VirVarSeq, another pipeline to call low frequency vari-
ants at the codon level developed for Illumina data. MinVar employs
a more conservative approach in calling low frequency variants that
results in better precision at the cost of a slight decrease in recall.
It should be emphasized that VirVarSeq had to be run on our Illu-
mina data without the last step of its workﬂow (see Methods). The
impossibility to run this step on Miseq data has been reported to
VirVarSeq authors by other groups and is probably due to the pres-
ence of gaps in the distribution of quality scores. In order to show
how MinVar can be successfully applied to different sequencing
technologies, we  also applied it to data obtained with Roche 454 GS
Junior. Although Roche announced the imminent phase out of the
system, evaluating a pipeline also on this sequencing technology
is still of interest because it challenges versatility and robustness
of a tool and also because technologies still in use like Ion Torrent
share some similarities with it. In fact, since Illumina Miseq and
Roche 454 GS Junior use different chemistries, they offer a diverse
spectrum of coverage, read length, and nature of sequencing errors.
GS Junior has less but typically longer reads, and its most common
errors are indels (Beerenwinkel et al., 2012; Quin˜ones-Mateu et al.,
2014). We  demonstrate here that MinVar can be run with good
results on both platforms, indicating that it can be applied success-
fully to other sequencing platforms too, provided that the input is
in fastq format.
Turn over time is a critical component in diagnostics laborato-
ries. The time needed to perform variant calling is another crucial
factor in adopting deep sequencing platforms. On  a server equipped
with 32 AMD  processors introduced in 2010, MinVar runs 200,000
reads of a Miseq sample in less than twenty minutes. On  a more
recent server with 20 Intel processors the computing time was
cut to approximately one third. Even if run on many samples
sequenced together, this would be short when compared to the
lengthy process of library preparation and sequencing necessary
for both platforms and to the time for manual calling of variants in
Sanger sequencing.
Random sampling of 200′000 input reads that MinVar performs
on Miseq samples introduces a bias that could negatively affect the
variant calling, for example by missing those at low frequency. In
our setting, however, losing low frequency variants is unlikely even
for variants at 1% frequency. Further, at frequencies around 5% we
also observe an increased number of false positives, which can-
not be explained by a drop-off caused by sampling biases. Further
improvement of the software should include, for example, checks
for minimum acceptable and uniform coverage. For samples where
this is not the case, a strategy correcting for this skew is to be
chosen.
Although in the current study we analyzed only the pol gene
of HIV, it is worth noting that MinVar can be easily extended to
genotyping other regions as well as entirely different viruses (e.g.,
HBV, HCV).The majority of research efforts in the ﬁeld of low frequency
variant detection in viral populations have gone in two directions:
lowering the frequency threshold for the reliable detection of single
mutations and reconstructing whether or not mutations at different
rologic
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next-generation sequencing data and reliable estimation of HIV  quasispecies.
Nucleic Acids Res. 38, 7400–7409, http://dx.doi.org/10.1093/nar/gkq655.M. Huber et al. / Journal of Vi
ites occur together on the same viral strains. It has been observed
hat when a virus strain harbors mutations close enough to be cap-
ured by a single read, they can be detected more easily and at
 lower frequency than when mutations are far apart (McElroy
t al., 2013). The technique of inferring the co-occurrence of dif-
erent mutations on the same strain is also known as haplotype
econstruction. While this inference is straightforward when the
utations are close enough to be captured by the same read, it faces
 major obstacle when distances exceed the typical read length
global haplotype reconstruction) (Zagordi et al., 2012). Despite
his, reconstruction of haplotypes of artiﬁcial mixtures over the
ntire HIV genome has been successfully achieved (Giallonardo
t al., 2014). These efforts are paramount for exploring the poten-
ial and limits of NGS technologies and, for instance, for studying
irus evolution, but the application of these technologies in clin-
cal scenarios introduces additional constraints. Deep sequencing
rovides more information and is superior in sensitivity to conven-
ional population sequencing, but its adoption into the diagnostic
se in clinical laboratories has until now been slowed down by
 number of crucial factors: high cost, need for very large com-
utational resources, lack of or limited bioinformatic expertise
nd unclear regulations (Donaldson et al., 2015). Recent technol-
gy developments are greatly contributing to decreased cost and
impler/automated pipelines and there is little doubt that these
latforms will soon outcompete Sanger sequencing. Principles and
uidelines have to be implemented that results from tests based on
GS are reliable and useful for clinical decision making (Gargis et al.,
012). This makes the development of analysis tools, like MinVar,
hat allow interpretation of data without additional bioinformatics
nput, a necessity to allow wide spread use.
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